METHODS	The EARLY ACS ( Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome ) trial enrolled 9,406 patients with high-risk NSTEACS undergoing an early invasive strategy .\